Week in Review: VC 2012 Predictions and MediaMath Crowned King of DSPs
Posted by | December 16, 2011
In the latest VentureView report, the National Venture Capital Association and Dow Jones & Co. reported that 63 percent of VCs think their portfolio companies will become more valuable in 2012. In addition, 80 percent of CEOs of venture back companies believe their companies would grow in value in the next year.
VC backed companies also continue to fuel job creation. Despite some uncertainty, 86 percent of venture capital backed companies said they will increase headcount in 2012. Just four percent predicted a headcount decrease, and 10 percent said their staff levels would remain the same.
The sixth annual survey also shows enthusiasm for the IT sector. According to the results, a majority of VCs expect an increase in funding for consumer information technology and healthcare IT companies, and half see capital increasing for enterprise IT. From big data and the Internet of Things to mobility and social networking, innovations in business computing from the funded start-up community are driving us closer to Enterprise 3.0.
In partner company news:
- AdvantEdge Healthcare Solutions ranked #10 on New Jersey’s Fifty Fastest Growing Companies for 2011 by NJBIZ. The awards program celebrates New Jersey’s most dynamic companies who progressively contributed to the success of the state’s economic growth and stability.
- MediaMath was declared winner of demand-side platforms (DSPs) by Forrester Senior Analyst Joanna O’Connell who evaluated seven companies on 48 different criteria, such as data access and support; algorithmic optimization; leadership; and internal resources. MediaMath was given top marks for “excellent algorithmic optimization capabilities” and both “broad and deep” multichannel media and data access.
- Putney welcomed a new member to its management team, hiring Ted Smolenski as Vice President of Strategic Portfolio Planning. Smolenski brings valuable experience, strategic thinking, and deep analytical skills, as he plans to lead Putney’s portfolio process to analyze and recommend drug products for development, license, and acquisition.
- Tengion was featured in several presentations at the TERMIS North America Annual Conference from Dec. 11 to 14 in Houston. Tengion featured new data from the Company’s Neo-Urinary Conduit™ (NUC) and Neo-Kidney Augment™ (NUC) programs in its presentations.
To read more of our “Week in Review” series, please use the following feed: www.safeguard.com/WeekinReview. Wishing you a great weekend and a happy holiday season!
